

What do you need to know?

- The existing Royal College Resident ePortfolio program for tracking CBD elements ends December 2024
- University of Calgary's Cumming School of Medicine decided to transition to LGI Education (MedSIS 3C) before the end of 2024
- Phase 1 of the LGI Education (MedSIS 3C) implementation is targeted for release on October 2, 2024. Phase 1 includes CBD elements only (EPA/narrative observations and competence committee meeting/decision support).
- There will be three release waves through October to November 2024. The first wave includes 23 programs.
- Phase 2 is in the planning and development stage with a targeted release of July 2025. Phase 2 will include transitioning other workflows currently supported by one45 to LGI Education (MedSIS 3C).

What's in it for Preceptors?

- Mobile-friendly interface
- EPA template remains the same
- Residents can now pre-fill assessments OR submit forms on behalf of Preceptor (with verbal consent)

Options for Residents: Send a "blank" form to the Evaluator (preceptor gets an email notification with a link to form) Prefill the form and send to the Evaluator (preceptor gets an email notification with link to form — can edit as needed) Complete the form "Submit as Evaluator" (preceptor gets an email notification) (Residents should get permission from you to do this!)



The system will be released in 3 program "waves". Go Live for Wave 1 is October 2, 2024.

System Access

• Your User / Login ID is an existing Ucalgary or AHS (or affiliated) email address the program has on file. More information will be provided closer to October 2.

Note: Even if your Program is not included in Wave 1, we are targeting to give you system access beginning October 2.

System Notifications

The system does not allow personal email addresses to login (must be either UCalgary or AHS (or affiliate)

Training

- All users, including Residents, Preceptors, Academic Advisors and Competence Committee Members, will have access to training materials, including Quick Reference Guides on the PGME website. https://cumming.ucalgary.ca/pgme/medsis-information
- Links to these materials will be available late September 2024

Are you an Academic Advisor or Competence Committee Member?

• Task-specific training materials will be available to you on the PGME website



Targeted Go-live dates by Program

Wave 1 - October 2		Wave 2 - October 23	Wave 3 - November 13
Anesthesiology	Neurosurgery	Critical Care Medicine	Child and Adolescent Psychiatry
Cardiac Surgery	Obstetrics and Gynecology	Gastroenterology - Adult	Clinical Pharmacology and Toxicology
Cardiology	Orthopedic Surgery	Geriatric Medicine	Developmental Pediatrics
Dermatology	Otolaryngology - Head and Neck Surgery	Gynecologic Oncology	Medical Genetics
Diagnostic and Clinical Pathology (GP)	Pediatric Infectious Disease	Hematology - Adult	Medical Oncology
Diagnostic and Molecular Pathology (AP)	Pediatrics	Nephrology - Adult	Neonatal-Perinatal Medicine
Diagnostic Radiology	Plastic Surgery	Ophthalmology	Pain Medicine
Emergency Medicine	Psychiatry	Pediatric surgery	Palliative Medicine
General Internal Medicine	Surgical Foundations	Physical Medicine and Rehabilitation	Pediatric Emergency Medicine
General Surgery	Vascular Surgery	Respirology - Adult	Pediatric Gastroenterology
Infectious Diseases - Adult		Rheumatology - Adult	Pediatric Hematology Oncology
Internal Medicine			Pediatric Nephrology
Neurology - Adult			Pediatric Neurology
			Pediatric Respirology
			Radiation Oncology

Phase 1 of the LGI Education (MedSIS 3C) implementation **includes CBD elements only** (EPA/narrative observations and competence committee meeting/decision support).

All other forms that exist in one 45 (ITERS, daily forms, faculty evaluations, etc.) will continue to be accessed through one 45 for the current academic year.

Note: Programs that are not listed do not have active CBD Residents. The remaining programs will be transitioned to MedSIS 3C in July 2025.



Using an AHS email address?

Watch for this email – it is NOT spam.

Check both your @ucalgary.ca and your AHS (or affiliated) email for welcome instructions.

If your UserID is a UCalgary email, you will receive one email from MedSIS 3C with your login information

If your UserID is an AHS email, you will receive two emails:

1st email, comes from Microsoft requesting approval to access MedSIS 3C (you must click accept).

2nd email, comes from MedSIS 3C, with your login information.

From: Microsoft Invitations on behalf of University of Calgary <invites@microsoft.com>

rom: Microsoft Invitations on behalf of University of Calgary invitations on behalf of University of Calgary invitations on behalf of University of Calgary invited you to access applications within their organization ubject: University of Calgary invited you to access applications within their organization
You don't often get email from invites@microsoft.com. Learn why this is important
aution - This email came from an external address and may contain unsafe content. Ensure you trust this sender before opening attachments or clicking any links in this message
Please only act on this email if you trust the organization represented below. In rare cases, individuals may receive fraudulent invitations from bad actors posing as legitimate companies. If you were not expecting this invitation, proceed with caution. Organization: University of Calgary Domain: uofc.onmicrosoft.com
If you accept this invitation, you'll be sent to https://medsis.ucalgary.ca/ . Accept invitation
This invitation email is from University of Calgary (<u>uofc.onmicrosoft.com</u>) and may include advertising content. <u>Read University of Calgary's privacy statement</u> . Microsoft Corporation facilitated sending this email but did not validate the sender or the message. Microsoft respects your privacy. To learn more, please read the <u>Microsoft Brivacy Statements</u> . Microsoft Corporation, One Microsoft Way, Redmond, WA 88052
his message and any attached documents are only for the use of the intended recipient(s), are confidential and may contain privileged information. Any unauthorized review, use, retransmission, or other disclosure is strictly prohibited. If you have eceived this message in error, please notify the sender immediately, and then delete the original message. Thank you.